Malaysiakini
NEWS

Gilead prices Covid-19 drug candidate Remdesivir at US$2,340 per patient

Reuters

Published
1

Gilead Sciences Inc has priced its Covid-19 drug candidate Remdesivir at US$2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at US$390.

The price for US private insurance companies will be US$520 per vial, the drugmaker said, which equates to US$3,120 per patient for a treatment course using six vials of Remdesivir.

Share this story

Comments

By posting a comment, you agree to our Terms & Conditions as stipulated in full here

TERMS & CONDITIONS

Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

REPORT VIOLATORS

Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.